Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences is a promising biotechnology company with two strong segments, Cancer Vaccines and CAR-T Therapies. The recent update demonstrates the potential of the breast cancer vaccine in immune activation and the lira-cel program in addressing unmet needs in ovarian cancer treatment. While the programs are in early stages, the reported signals support continued clinical advancement and potential for strong investor interest. Further catalysts ahead, such as safety and efficacy data from the phase 1 trial and updates on dose escalation progress, will be key in shaping investor perception of the company's potential.

Bears say

Anixa Biosciences is facing several fundamental challenges that could hinder its success in the oncology market. These include a lack of significant financial resources, potential difficulties in obtaining regulatory approval for its therapies, and the competitive landscape with established biotech companies dominating the market. Additionally, the company's limited patent licensing activities suggest a lack of diverse revenue streams.

ANIX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 2 analysts, ANIX has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.